Thoracic Cancer: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner
Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC
MD Anderson Cancer Center
J Adv Pract Oncol 2021;12(6):586-593 |
© 2021 Harborside™
Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC, of MD Anderson Cancer Center, reviews important research in thoracic cancers presented at the 2021 ASCO Annual Meeting, including atezolizumab in early-stage lung cancer, the addition of doublet chemotherapy to doublet immunotherapy in advanced-stage NSCLC, the first-in-class KRAS G12C inhibitor sotorasib, and the combination of amivantamab and lazertinib. Coverage provided by The ASCO Post.
For access to the full length article, please sign in